Strategic SBIR Opportunity ScitoVation recently secured a 2.04M Phase II SBIR grant from NIEHS, indicating strong government funding potential and validation of its PBPK modeling and toxicology capabilities. Sales outreach can target government contractors, NIH institutes, and partners seeking translational research and risk assessment tools.

PBPK Model Lead The company launched ScitoSim, a PBPK modeling tool, and has leaders who pioneered PBPK in chemical disposition. This positions ScitoVation as a go-to partner for pharmacokinetic modeling projects, exposure extrapolation, and computational toxicology services for pharma, agrochemical, and consumer product clients.

Cell-Based Assay Focus ScitoVation emphasizes customized cell-based assays to determine safety and interpret genetic data for toxicity. Target opportunities include early safety screening for pharmaceuticals, food ingredients, and cosmetic or chemical entities seeking in vitro safety profiles and mechanism-of-action insights.

Leadership & Talent With hires in computational toxicology leadership and a Chief Scientific Officer, ScitoVation illustrates strong scientific credibility and ongoing capacity to take on complex, regulatory-driven toxicology projects for clients needing reliable toxicity assessments and data interpretation.

Growth Signals Revenue in the low to mid-range enterprise bracket and active product development plus recent financing suggest scalability and readiness to take on larger or recurring projects, including long-term CRO partnerships, NAMs reporting, and multi-project collaborations.